Anne Louise T. S.
- Country
- Denmark
- Department
- Department of Haematology
Research Overview
- Adaptive Platform Trial for Dose Optimization of Ibrutinib‑Based Combination Therapy in Adult Patients with Haematological Malignancies (BLOOD-dose)
- Phase II Evaluation of Azacitidine and Low-Dose Venetoclax in Acute Myeloid Leukemia with Multi-Omics and Ex Vivo Drug Screening Integration
- Phase 3 Randomized Double-Blind Study of PF-06821497 and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Data & Insights
Has run more than one trial at 53 of 270 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in the treatment of acute myeloid leukemia (AML), with particular focus on developing innovative therapeutic approaches for this aggressive blood cancer.
- Blood Cancer Treatment
- Leukemia Management
- Hematologic Malignancies
The investigator's work encompasses evaluation of novel combination therapies for improving outcomes in AML patients.
Therapeutic Innovation
The research focus includes investigating combination treatment approaches utilizing targeted therapies and established agents to enhance treatment efficacy in hematologic conditions.
- Novel Drug Combinations
- Treatment Optimization
- Response Assessment
Key interests include developing strategies to improve treatment responses in blood cancer patients.
Clinical Assessment
The investigator focuses on evaluating treatment efficacy parameters and response criteria in hematologic malignancies, including complete remission rates and overall response outcomes.
- Response Evaluation
- Clinical Outcomes
- Treatment Assessment
Expertise includes comprehensive evaluation of therapeutic responses in blood cancer treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.